CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

@article{Blad1998CRITERIAFE,
  title={CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION},
  author={Joan Blad{\'e} and Diana Samson and Donna Ellen Reece and Jane F. Apperley and Bo Bj{\"o}rkstrand and G{\"o}sta Gahrton and Morie A. Gertz and Sergio Giralt and Sundar Jagannath and David H. Vesole},
  journal={British Journal of Haematology},
  year={1998},
  volume={102}
}
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for about 10% of haematological malignancies. The disease is characterized by the clonal proliferation of plasma cells which produce a monoclonal immunoglobulin heavy and/or light chain (paraprotein, M-protein or Mcomponent). This patient-specific paraprotein is present in the serum and/or urine of all patients except in the 1–2% of patients with non-secretory myeloma. Typical clinical and laboratory features in patients with… 
Symposium 6A: Minimal residual disease in bone marrow disorders
TLDR
In three patients a molecular remission after DLI is now sustaining for more than 48 months, suggesting a curative potential of adoptive T-cell therapy in MM.
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma
TLDR
Novel therapies, including lenalidomide, thalidomides and bortezomib, have transformed the clinical management of MM and are increasingly recognized as potent therapies in overcoming resistant disease, with improvements in survival being seen, even in the relapsed and refractory setting.
Pharmacogenetic studies in multiple myeloma
TLDR
The pathological development of MM starts with the emergence of an asymptomatic premalignant stage of clonal plasma cell proliferation known as “monoclonal gammopathy of undetermined significance” (MGUS), occurring in about 3% of individuals above the age of 50.
Recent advances in the management of multiple myeloma.
TLDR
Simplified criteria for staging, uniform response criteria, more sensitive methods for detection of residual disease (immunofixation and free light chain assay), and recognition of potential adverse cytogenetic and genomic abnormalities have further refined the management of patients with myeloma.
Diagnosis and staging
TLDR
Diagnostic criteria from the International Myeloma Working Group include clonal bone marrow plasma cells ≥10 %, the presence of serum and/or urinary monoclonal protein, and evidence of end-organ damage, which can be attributed to the underlying plasma cell proliferative disorder.
IgD multiple myeloma—a clinical profile and outcome with chemotherapy and autologous stem cell transplantation
TLDR
It appears that outcome for IgD myeloma remains poor with chemotherapy and appears to be superior with autologous peripheral blood stem cell transplantation, and larger studies are needed to confirm these findings.
Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens
TLDR
The data indicate that after treatment with TBR some patients with myeloma show discordant responses of the monoclonal protein levels and the bone marrow or extramedullary plasmacytosis, which may have practical implications for assessment of response and follow up of patients treated with T BR.
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
TLDR
It is proposed that the thresholds for diagnosis be re-examined and consensus recommendations are made for diagnosis, as well as, response and progression criteria.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
TLDR
An update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation is provided to help clinicians ensure the most appropriate care for patients with Myeloma in everyday clinical practice.
...
...

References

SHOWING 1-10 OF 55 REFERENCES
Current Issues in Cancer: Multiple myeloma
TLDR
Who should be treated for multiple myeloma and the benefits that may be expected from the treatments available are looked at.
The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.
TLDR
It is concluded that the combination of the four drugs is not better than melphalen and prednisone for inducing responses or prolonging the survival of patients with myeloma.
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.
TLDR
This therapy has achieved high response rates and prolonged progression-free survival in some patients and proven to have acceptable toxicity, however, relapses post-BMT, coupled with slow engraftment post- BMT in heavily pretreated patients, suggest that such treatment strategies should be used earlier in the disease course.
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone
TLDR
No correlation between response and survival is suggested, partially because of inadequate response assessment criteria and partially because no existing treatment is curative (although current therapeutic approaches may prevent death from complications).
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors.
TLDR
Immunoglobulin gene fingerprinting, a PCR-based technique, is used to evaluate minimal residual disease in 5 patients in unmaintained CR 9-60 months after allogeneic BMT, suggesting that cure of multiple myeloma may be a realistic goal.
Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation
TLDR
It is concluded that autografting in myeloma is most effective when applied early in the course of disease in younger, chemotherapy‐responsive patients and alpha‐interferon maintenance treatment seems to be beneficial with respect to improved survival.
Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients
TLDR
The results indicate that, in responding patients, neither the degree of response nor the response kinetics has a significant influence on survival, however, the response to therapy is associated with a significantly longer survival in MM patients.
MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS.
TLDR
These results are based on a study of 165 patients who received the drug for at least 60 days (an "adequate trial") and twenty percent of the patients who started the study did not reach adequate trial status because of death, complications, or loss to follow-up.
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
TLDR
Compared to ST, dose intensification with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but also significantly extending EFS and OS in previously untreated patients with MM.
...
...